Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.
Advanced head and neck cancers are difficult to manage despite the large treatment arsenal currently available. The multidisciplinary effort to increase disease-free survival and diminish normal tissue toxicity was rewarded with better locoregional control and sometimes fewer side effects. Nevertheless, locoregional recurrence is still one of the main reasons for treatment failure. Today, the standard of care in head and neck cancer management is represented by altered fractionation radiotherapy combined with platinum-based chemotherapy. Targeted therapies as well as chronotherapy were trialled with more or less success. The aim of the current work is to review the available techniques, which could contribute towards a higher therapeutic ratio in the treatment of advanced head and neck cancer patients.
School of Chemistry and Physics, University of Adelaide, Adelaide, SA 5000, Australia ; Faculty of Science, University of Oradea, 410087 Oradea, Romania.
Loredana G
LG
Marcu
D017024:Chemotherapy, Adjuvant; D019454:Chronotherapy; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans
D002945:Cisplatin